近日,先声诊断与吉林大学第二医院合作,首次报道了一名携带SLC8A1 / LINC01913-ALK新型ALK融合的IIB肺腺癌患者,该患者服用克挫替尼后一直未复发,该案例发表于Investigational New Drugs(IF=3.651)[1]。 案例分享一名60岁男性在体检时发现...
ALK rearrangements often occur at a common breakpoint in exon 20 of the genome. SLC8A1-ALK, a novel fusion protein partner, comes from exon 2 of the SLC8A1 gene rearranged with exon 20 of the ALK gene. Here, we reported a patient with advanced lung adenocarcinoma harboring a SLC8A1-ALK...
此外,非小细胞肺癌的微乳头型与预后不良有关。近年来,ALK酪氨酸激酶抑制剂(ALK-TKIs)克唑替尼被广泛用于治疗ALK融合的晚期NSCLC患者。患者的生存结果变得非常有希望,这反映了探索ALK-TKIs在已切除的早期NSCLC中应用的必要性。 近日,先声诊断与吉林大学第二医院合作,首次报道了一名携带SLC8A1 / LINC01913-ALK新型ALK...
Patient survival outcomes have become highly promising, reflecting the necessity of exploring the application of ALK-TKIs in resected, early stage NSCLC with ALK rearrangements. A 60-year-old Chinese man was diagnosed with stage IIB lung adenocarcinoma harboring a novel SLC8A1/LINC01913 intergenic ...